PHARMACOLOGY药理学
PHARMACOLOGY(英文缩写 PHARMACOLOGY),ISSN 0031-7012,eISSN 1423-0313,中文译名:药理学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.429 | Q3 |
| 2022 | 3.100 | Q3 |
| 2023 | 2.900 | Q2 |
| 2024 | 3.200 | Q2 |
| 2025 | 2.800 | Q3 |
PHARMACOLOGY 最新收录文献
-
1. Comparative analysis of infarct-reducing properties of ß1 -, ß2 -, and ß3 -adrenergicreceptor ligands in ischemia and reperfusion of the heart.
PMID:日期:2026-09-15In-hospital mortality in patients with acute myocardial infarction and cardiogenic shock can reach 50%. This is because there are currently no drugs approved for clinical use that can radically reduce infarction size and prevent the development of cardiogenic shock. β- Adrenergic receptor (β-AR) ligands could become such drugs. This article presents a comparative study of the cardioprotective properties of β-AR ligands in ischemia and reperfusion (I/R) of the heart. The study was performed in male Wistar rats. Coronary artery occlusion (CAO, 45 min) and reperfusion (120 min) were carried out in anesthetized animals. Fifteen minutes before CAO the following β-AR ligands were injected intravenously: the selective β 1 -AR antagonist atenolol, β 1 - and β 2 -AR antagonist sotalol, β 1 -, β 2 -, and β 3 -AR antagonist bupranolol, selective β 2 -AR antagonist ICI-118,551, selective β 3 -AR antagonist L- 748,337, and selective β 2 -AR agonist formoterol. It was evaluated the infarct size/area at risk (IS/AAR) ratio. Sotalol, bupranolol, atenolol, ICI-118,551, and L-748,337 decreased heart rate. Formoterol increased heart rate. Atenolol only reduced the IS/AAR ratio. β 1 -AR blockade increases cardiac tolerance to I/R in vivo. β 2 -AR blockade and β 2 - AR stimulation do not affect cardiac resistance to I/R in vivo. β 3 -AR blockade does not affect cardiac resistance to I/R in vivo.
-
2. Clinical Evidence in Respiratory and Urinary Tract Infections: Focus on Ceftibuten.
PMID:日期:2026-08-31Antimicrobial resistance (AMR) is one of the most pressing global health problems, resulting from the misuse and overuse of antibiotics across various sectors, which has led to the emergence and spread of resistant microorganisms. AMR occurs when microorganisms no longer respond to antibiotics. In Italy alone, AMR is responsible for over 10,000 deaths each year, exceeding 40% of all AMR, attributable deaths in the EU/EEA. This alarming trend highlights the urgent need to preserve effective treatment options and to re-evaluate the role of well-established oral antibiotics with a favourable pharmacological and microbiological profile. Ceftibuten is an oral third-generation cephalosporin with potent activity against many Gram-negative and some Gram-positive pathogens, including several Gram-negative pathogens. It is approved for the treatment of respiratory and urinary tract infections (UTIs), both uncomplicated and complicated, in adults as well as in children. This review discusses clinical and pharmacological data supporting ceftibuten's efficacy, safety, pharmacokinetics, and microbiological spectrum. Moreover, the paper discusses its potential role in contemporary clinical practice, especially considering recent supply interruptions and increasing resistance patterns. Ceftibuten represents an oral treatment option for respiratory and UTIs, particularly where resistance to other agents limits therapeutic choices. Its favourable pharmacokinetic profile, safety both in paediatric and adult populations, and efficacy against key resistant pathogens support. use within approved indications. Finally, this antibiotic offers a favourable safety profile for both patients allergic to penicillin and cephalosporins, particularly third- and fourth-generation cephalosporins. Ensuring continued access to this antibiotic may contribute to appropriate management of infections in both community and hospital settings.
-
3. Clinical characteristics, treatment, and outcomes of vancomycin-induced linear IgA bullous dermatosis.
PMID:日期:2026-08-14This study aimed to elucidate the clinical attributes of vancomycin-induced linear IgA bullous dermatosis (LABD) to enhance diagnostic, therapeutic, and preventive approaches. We conducted a retrospective analysis of vancomycin-induced LABD cases by reviewing the literature in Chinese and English databases up to July 31, 2025. A total of 104 patients were identified, with a median age of 70 years (range 29, 92). The median time to onset of LABD was 9 days (range 0.5, 20), with 80.7% of patients presenting symptoms within two weeks. The predominant clinical manifestations included blisters (87.1%), vesicles (41.3%), erythema (52.9%), and papules (19.2%), frequently accompanied by pruritus (18.3%). Mucosal involvement was noted in 26.9% of cases. Histopathological examination typically demonstrated inflammatory cell infiltration (79.8%). Direct immunofluorescence assays revealed linear IgA deposition along the basement membrane zone. After stopping vancomycin and receiving treatment, all patients exhibited significant improvement in their skin lesions. Clinicians should recognize LABD as a serious but infrequent adverse reaction to vancomycin. Increased vigilance is crucial during the initial two weeks of vancomycin treatment, especially in elderly patients over 60 years of age. LABD recovered completely after withdrawal of vancomycin and other treatments.
-
4. An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.
PMID:日期:2026-08-10Research on the therapeutic benefits of psychedelics, particularly psilocybin, is becoming increasingly popular. Unfortunately, most psychedelic research overlooks the menstrual cycle as a biological variable, raising concerns about the safety and efficacy of findings for individuals who menstruate. Given the established effects of estradiol and progesterone (and metabolites) on serotonin receptor density and function, it is plausible that the subjective experience, efficacy, and side effect profile of psychedelics may vary significantly across the different phases of the menstrual cycle. Furthermore, the tolerance effects of psilocybin when taken on consecutive days are unknown. The PsiMenis trial will comprises two sub-studies: PsiMen-M, which will assess the potential for the menstrual cycle to affect the response to low-dose psilocybin in healthy menstruating persons, and PsiMen-T, which will test for potential tolerance effects. Psilocybin (5 mg) will be administered during different menstrual cycle phases in 21 healthy participants for PsiMen-M, and 12 for PsiMen-T. Effects on subjective experience, brain/cognitive function, and pharmacokinetics will be measured by the Drug Effects Questionnaire, exploratory task-based electroencephalography (EEG), and blood plasma sampling. Safety and any clinically significant modifications of psilocybin will be monitored by laboratory and vital signs tests. Tolerance to psilocybin will be assessed by administering the drug for three consecutive days. This study will determine whether low-dose psilocybin effects vary across the menstrual cycle, addressing a key gap in psychedelic research. Findings may inform the development of serotonergic treatments for menstrual-cycle-related mood disorders and improve the design of future psychedelic trials by accounting for hormonal fluctuations.
-
5. Dexmedetomidine Alleviates Cardiomyocyte Senescence Induced by Ischemia-Reperfusion Injury via Inhibiting the MDH2/NF-κB Pathway.
PMID:日期:2026-08-05Myocardial ischemia-reperfusion (I/R) injury represents a key contributor to cardiac dysfunction and is associated with cardiomyocyte senescence. Dexmedetomidine (Dex) exhibits significant myocardial protective effects, but its molecular mechanisms in alleviating I/R-induced cardiomyocyte senescence remain unclear. In this study, an I/R injury model was established in C57BL/6 mice. An in vitro injury model of H9C2 cardiomyocytes was constructed using the oxygen-glucose deprivation/reoxygenation method to evaluate the effects of Dex on senescence in myocardial tissue and cardiomyocytes. Histopathological changes were assessed using hematoxylin and eosin and Masson staining, while cellular senescence was evaluated through senescence-associated β-galactosidase staining. The levels of myocardial infarction-related factors were detected by ELISA. The expression of senescence-related markers (p27, p21, and p16) was measured by qRT-PCR and WB, and apoptosis was measured by TUNEL assay. Cell viability, proliferation, and oxidative stress (OS) levels were assessed by CCK-8, EDU, and DCFH-DA probes. In vivo and in vitro experiments showed that Dex alleviated I/R-induced myocardial histopathological damage, improved cardiomyocyte viability and proliferation, reduced OS, and suppressed cellular senescence. Mechanistic studies revealed that Dex inhibited activation of the NF-κB pathway by downregulating malate dehydrogenase 2 (MDH2), thereby attenuating cardiomyocyte senescence. Dex significantly mitigates I/R injury-driving cardiomyocyte senescence by blocking the MDH2/NF-κB signaling, providing a potential therapeutic strategy for ischemic heart disease.
-
6. The Co-Regulation of NLRP3 Inflammasome and Autophagy for Cardiovascular Diseases.
PMID:日期:2026-08-03Cardiovascular diseases (CVDs) represent a significant global public health challenge. Activation of the NLRP3 inflammasome contributes to CVD pathogenesis, while autophagy mitigates the condition by eliminating harmful metabolites. Furthermore, NLRP3 inflammasome and autophagy co-regulate CVDs by enhancing autophagic processes, inhibiting inflammasome activity, and reducing inflammatory responses, thus playing a pivotal role in the disease's pathophysiology. Certain pharmacological agents have been shown to inhibit NLRP3 inflammasome activity by promoting autophagy, thereby ameliorating disease pathology. This review underscores the pivotal roles of NLRP3 inflammasome and autophagy in CVDs and examines the regulatory effects of specific drugs on these processes.
-
7. Comparative Efficacy and Safety of Telitacicept versus Belimumab in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
PMID:日期:2026-07-11This study was designed to assess the comparative efficacy and safety of telitacicept and belimumab in adult patients diagnosed with systemic lupus erythematosus (SLE). We systematically searched MEDLINE, Embase, and Web of Science from database inception through March 2026 to identify retrospective observational studies comparing telitacicept and belimumab in adult patients with SLE. A meta-analysis was conducted to pool efficacy data, reporting odds ratios (ORs) and 95% confidence intervals (CIs) for treatment response. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; Registration No. CRD420261420984). Out of 215 records screened, 5 studies (676 patients; 340 receiving telitacicept and 336 receiving belimumab) met the inclusion criteria following full-text assessment. Telitacicept was associated with significantly improved rates of lupus low disease activity state (LLDAS) at 24 weeks (OR = 1.87, 95% CI = 1.03-3.39, p = 0.041; 2 studies, I2 = 0%, p = 0.92) and complete renal response at 24 weeks (OR = 2.38, 95% CI = 1.10-5.15, p = 0.027; 2 studies, I2 = 0%, p = 0.88) compared to belimumab, utilizing fixed-effects models due to absence of heterogeneity. The Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at 24 weeks (OR = 2.02, 95% CI = 1.04-3.91, p = 0.038; 1 study) and complete renal response at 52 weeks (OR = 2.67, 95% CI = 1.17-6.09, p = 0.019; 1 study) were also significantly greater with telitacicept. Prednisone tapering to ≤7.5 mg/day at 24 weeks approached statistical significance (OR = 1.56, 95% CI = 1.00-2.43, p = 0.049; 1 study). Analysis of safety endpoints showed no statistically significant differences between groups for overall adverse events (OR = 1.21, 95% CI = 0.96-1.53, p = 0.088; 3 studies, I2 = 0%, p = 0.95), or serious adverse events (OR = 0.68, 95% CI = 0.43-1.08, p = 0.072; 2 studies, I2 = 0%, p = 0.89). Telitacicept suggests greater efficacy over belimumab in achieving LLDAS, SRI-4 response, complete renal response, and reduction in prednisone dosage in patients with SLE, without notable differences in rates of adverse events, serious adverse events, or infections.
-
8. Inflammatory Conditions Determine Glucocorticoid Effects on Spontaneous or Immunoglobulin-Induced Neutrophil Death.
PMID:日期:2026-07-08Neutrophils play a central role in the pathogenesis of inflammatory and autoimmune disorders. While glucocorticoids are potent anti-inflammatory agents, they are known to promote neutrophil survival, which may worsen neutrophil-driven conditions. In contrast, intravenous immunoglobulin (IVIG) and IgA promote neutrophil death, offering potential therapeutic benefits in neutrophil-predominant diseases. Neutrophils isolated from healthy donors and patients with acute appendicitis, together with an ex vivo appendicitis tissue model, were used to evaluate the effects of IgA, IVIG, and dexamethasone on neutrophil survival and apoptosis. In this study, we found that dexamethasone effects on neutrophil survival and its interaction with IVIG-induced neutrophil death are differentially influenced by cytokines or microbial components. Dexamethasone inhibited IVIG-induced neutrophil death in unprimed or granulocyte-macrophage colony-stimulating factor-primed cells, but not in lipopolysaccharide-primed cells. The effects of dexamethasone were mediated by glucocorticoid receptor signaling and genomic regulation, suppressing apoptotic and non-apoptotic death pathways. In an ex vivo model of appendicitis, despite dexamethasone's pro-survival effects, neutrophils underwent significant death in response to IVIG or IgA. These findings highlight the context-dependent nature of dexamethasone's effects and underscore the importance of local inflammatory or microbial factors in therapeutic outcomes.
-
9. Long-Term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.
PMID:日期:2026-07-06Anifrolumab, a type I interferon receptor antagonist, has shown effectiveness in treating moderate-to-severe systemic lupus erythematosus (SLE). To fully understand its long-term efficacy, glucocorticoid (GC)-sparing potential, and cumulative safety profile in everyday clinical practice, it is essential to combine up to 4 years of long-term extension (LTE) trial data with emerging real-world evidence (RWE). A systematic literature search was performed across major electronic databases to identify phase 2/3 randomized controlled trials (RCTs), LTE studies, and RWE cohorts assessing anifrolumab in SLE. Comparative odds ratios (ORs) for RCTs were calculated using the Mantel-Haenszel method, while pooled proportions for single-arm RWE cohorts were estimated using a random-effects model. Primary outcomes included BICLA response, Lupus Low Disease Activity State (LLDAS), GC reduction (to ≤7.5 mg/day), and herpes zoster (HZ) incidence. Ten studies were included, comprising phase 2/3 RCTs, their LTEs (TULIP-LTE, MUSE-LTE), and four European RWE cohorts. In the RCTs (N = 1,093), anifrolumab significantly improved BICLA responses compared to placebo (pooled OR 1.85, 95% CI 1.42-2.41, p < 0.001) and enhanced the likelihood of achieving a target GC dose of ≤ 7.5 mg/day (OR 2.24, 95% CI 1.52-3.29, p < 0.001). In the pooled RWE cohorts (N = 294), the estimated attainment rate for LLDAS at 6-12 months was notably high at 75.8% (95% CI 68.4-82.5%). Additionally, 72.5% of real-world patients achieved a >50% reduction in GC dosage. Regarding safety, there was no significant increase in overall serious adverse events (OR 0.82, p = 0.25). Although anifrolumab was linked to a higher risk of HZ (OR 3.45, 95% CI 1.95-6.10, p < 0.001), both LTE and RWE data indicated that these cases were mainly mild to moderate and manageable. Anifrolumab offers rapid, strong, and sustained disease control while providing significant GC-sparing effects in both tightly controlled clinical trials and diverse real-world populations. The long-term safety profile remains stable; however, preventative measures, such as HZ vaccination, should be implemented as part of standard care.
-
10. Safety and Efficacy of Efbemalenograstim Alfa for Patients at Risk for Chemotherapy-Induced Neutropenia: A Systematic Review and Meta-Analysis.
PMID:日期:2026-07-04Chemotherapy-induced neutropenia (CIN) and its severe complication, febrile neutropenia, remain major challenges in oncology. Although granulocyte colony-stimulating factors (G-CSFs) have reduced the incidence of these complications, limitations related to dosing schedules, polyethylene glycol (PEG)-associated concerns, and pharmacokinetic variability persist. Efbemalenograstim alfa (F-627) is a novel non-PEGylated Fc fusion G-CSF designed for once-per-cycle administration. This systematic review and meta-analysis evaluated the efficacy and safety of efbemalenograstim alfa compared with placebo or standard G-CSFs in patients at risk of CIN. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD42024628001). MEDLINE, Embase, Cochrane Library, Web of Science, and <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> were searched from inception to October 22, 2025. Randomized controlled trials evaluating efbemalenograstim alfa in patients receiving myelotoxic chemotherapy were included. Efficacy outcomes included duration of severe neutropenia (DSN), incidence of severe neutropenia (ISN), and depth of absolute neutrophil count (ANC) nadir. Safety outcomes included adverse events, serious adverse events, and treatment discontinuations. Random-effects meta-analyses were performed. Five randomized controlled trials involving approximately 800 patients with breast cancer receiving myelotoxic chemotherapy were included. Compared with placebo or standard G-CSFs, efbemalenograstim alfa demonstrated comparable efficacy in reducing DSN during the first chemotherapy cycle (MD -0.32 days; 95% CI: -0.79 to 0.14) and ISN (RR 0.86; 95% CI: 0.73-1.03). A significant improvement in ANC nadir was observed (MD + 0.40 ×109/L; p = 0.0002). Rates of serious adverse events (RR 0.71; 95% CI: 0.29-1.70), adverse events, and treatment discontinuations were comparable between groups. Heterogeneity was primarily attributable to the inclusion of a placebo-controlled study. Efbemalenograstim alfa demonstrated efficacy and safety comparable to currently available long-acting G-CSFs for the prevention of CIN. Its Fc fusion structure enables once-per-cycle administration without PEGylation, supporting its potential as an alternative long-acting G-CSF. Further studies are needed to evaluate long-term outcomes and real-world effectiveness.